Bio News
The PAPOLA enzyme has been identified as a key factor that worsens disease in acute myeloid leukemia (AML). PAPOLA increases GSTM2 mRNA expression, reprograms metabolism and promotes the self-renewal of leukemia stem cells, according to a study published in Nature Cancer (IF 28). Cordycepin, a PAPOLA inhibitor, suppressed tumors in AML models, demonstrating its potential as a new treatment.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
